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The neural correlates of cognitive impairment in chronic obstructive pulmonary disease
(COPD) are not yet understood. Structural brain abnormalities could possibly be
associated with the presence of cognitive impairment through cigarette smoke,
inflammation, vascular disease, or hypoxemia in these patients. This study aimed to
investigate whether macrostructural brain magnetic resonance imaging (MRI) features
of cerebral small vessel disease (SVD) and hippocampal volume (HCV) are related
to cognitive performance in patients with COPD. A subgroup of cognitively high and
low-performing COPD patients of the COgnitive-PD study, underwent a brain 3T MRI.
SVD as a marker of vascular damage was assessed using qualitative visual rating scales.
HCV as a marker of neurodegeneration was assessed using the learning embedding for
atlas propagation (LEAP) method. Features of SVD and HCV were compared between
cognitively high and low-performing individuals using Mann Whitney U tests and
independent samples t-tests, respectively. No group differences were reported between
25 high-performing (mean age 60.3 (standard deviation [SD] 9.7) years; 40.0% men;
forced expiratory volume in first second [FEV1] 50.1% predicted) and 30 low-performing
patients with COPD (mean age 60.6 (SD 6.8) years; 53.3% men; FEV1 55.6% predicted)
regarding demographics, clinical characteristics, comorbidities and the presence of the
SVD features and HCV. To conclude, the current study does not provide evidence for a
relationship between cerebral SVD and HCV and cognitive functioning in patients with
COPD. Additional studies will be needed to determine other possible mechanisms of
cognitive impairment in patients with COPD, including microstructural brain changes
and inflammatory-, hormonal-, metabolic- and (epi)genetic factors.
Keywords: cerebral small vessel diseases, chronic obstructive pulmonary disease, cognition, hippocampus,
magnetic resonance imaging
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a highly
prevalent chronic disease which is primarily characterized by
progressive airflow limitation (Vestbo et al., 2013). Beyond
respiratory impairment, patients with COPD often suffer from
a variety of comorbid and biological conditions (Divo et al.,
2012; Vanfleteren et al., 2013). These biological changes may
have adverse effects on the brain leading to cognitive impairment.
General cognitive impairment is four times more likely to
occur in patients with COPD than in non-COPD controls
and involves several cognitive domains, such as psychomotor
speed, planning, memory and cognitive flexibility (Cleutjens
et al., 2017). Impairments in working and verbal memory
have been found in one out of three patients with COPD
(Cleutjens et al., 2017). Although the pathogenesis of cognitive
impairment in COPD has been searched in oxidative stress,
hypoxemia, systemic inflammation and comorbidities, the exact
pathways remain unknown (Dodd et al., 2010; Cleutjens et al.,
2014a; Lahousse et al., 2015). Structural brain abnormalities
are considered an important cause of cognitive impairment,
especially decreased hippocampal volume (HCV), which has
been associated with decreased memory (Soininen et al., 1994;
Schuff et al., 2009; Wolz et al., 2010b), and features of
cerebral small vessel disease (SVD; Cai et al., 2015). SVD
refers to pathological processes affecting the small arteries,
arterioles, venules and capillaries of the brain. For example,
chronic hypoperfusion can occur, whereby the supply of
oxygen and nutrients to the brain tissue is slowly cut (Cai
et al., 2015). Hypoxemia is thought to act in an additive
manner in the development of structural brain abnormalities
(Miyamoto and Auer, 2000). Structural brain abnormalities
associated with SVD can be seen on magnetic resonance
imaging (MRI) as white matter hyperintensities (WMHs),
lacunes, cerebral microbleeds and perivascular spaces (PVS).
The main risk factors for SVD are increased age and
hypertension.
In comparison to control participants, COPD patients showed
smaller HCV (Li and Fei, 2013), reduced white matter integrity
and regional gray matter density (Dodd et al., 2012; Zhang et al.,
2012), periventricular white matter lesions (van Dijk et al., 2004),
disturbed functional activation of gray matter (Dodd et al., 2012),
and a higher prevalence of cerebral microbleeds (Lahousse et al.,
2013). Possible mechanisms, common in COPD, which may
contribute to brain abnormalities and cognitive impairment are
cigarette smoke, inflammation, vascular disease and hypoxemia
(Dodd et al., 2010). Yet, the relationship between structural brain
abnormalities, especially HCV and features of SVD and cognitive
functioning in COPD remains unexplored.
In order to verify whether SVD and HCV may explain the
level of cognitive functioning in patients with COPD, this study
aimed to assess whether and to what extent SVD and HCV
differ between COPD patients with high and low cognitive
performance. A priori, we hypothesized that COPD patients with
low cognitive performances are characterized by a higher SVD
load, and smaller HCV compared to COPD patients with high
cognitive performances.
MATERIALS AND METHODS
Design
This cross sectional study is part of a longitudinal study
(COgnitive-PD study) aimed at mapping and understanding
neuropsychological functioning in patients with COPD. Details
of the methodology of this study and data concerning cognition
have been described before (Cleutjens et al., 2014b, 2017).
Study Population
For this study, we selected the first 30 cognitively low-performing
and the first 25 high-performing patients with COPD during
inclusion of the COgnitive-PD study (n = 183) who were
willing to undergo brain MRI. Six core tests of the detailed
neuropsychological test battery from the Cognitive-PD study
(Table 1) were used to distinguish cognitively high-performing
individuals from low-performing individuals (Burgmans
et al., 2009; for details about the tests, please see the
Cognitive-PD study protocol (Cleutjens et al., 2014b)).
In addition to the exclusion criteria of the COgnitive-PD
study (Cleutjens et al., 2014b), patients were not eligible
if they had contraindications to undergo a brain MRI
(claustrophobia, a cardiac pacemaker, a cochlear implant, a
neurostimulator, or other metal implants in the body). The
study was approved by the Medical Ethics Committee of the
Maastricht University Medical Centre (NL45127.068.13). All
patients provided written informed consent to participate in the
study.
Brain MRI Acquisition
Patients had brain MRI on a research-dedicated 3-T MRI
scanner (Siemens, Netherlands) operated by research-dedicated
technical staff in the Maastricht University Medical Center.
Sequences included T1-weighted sagittal sequence (TR = 8.14ms,
TE = 3.72 ms, FA = 8◦, FOV = 256× 256× 155 mm, acquisition
matrix = 256× 256, number of slices = 155, voxel size = 1.00 mm
isotropic), T2-weighted transversal sequence (TR = 3000 ms,
TE = 80 ms, FA = 90◦, FOV = 230 × 230 × 154 mm, acquisition
matrix = 512 × 512, number of slices = 28, slice gap = 0.50 mm,
voxel size = 0.45 × 0.45 × 5.5 mm), fluid-attenuated
inversion recovery (FLAIR) sagittal sequence (TR = 4800 ms,
TE = 275 ms, TI = 1650 ms, FOV = 250 × 250 × 154 mm,
acquisition matrix = 240 × 240, number of slices = 275, slice
gap = 0.56 mm, voxel size = 1.04 × 1.04 × 0.56 mm), and
T2∗-weighted transversal sequence (TR = 844 ms, TE = 16 ms,
FA = 18◦, FOV = 230 × 230 × 154 mm, acquisition
matrix = 512 × 512, number of slices = 28, slice gap = 0.50 mm,
voxel size = 0.45× 0.45× 5.5 mm).
MRI Analysis
All MRIs were analyzed blinded to patient’s cognitive status.
WMHs (Figure 1A) were classified as periventricular WMHs
(PVWMHs; localized around the lateral ventricles) or deep
WMHs (DWMHs; localized within the deep WM) on the
Fazekas scale ranging from 0 to 3, using FLAIR and T2-weighted
images (Fazekas et al., 1987). Additionally, the age-related
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TABLE 1 | Cognitive performance per core subtest on the COgnitive-PD study neuropsychological test battery.
High-performing COPD
patients (n = 25)
Low-performing COPD
patients (n = 30)
Outcome measure Mean (SD) Z ≤ −1 Mean (SD) Z ≤ −1
VVLT total recall (number correct: 0–75)∗ 54.4 (8.6) 0.0% 35.4 (9.1) 50.0%
VVLT delayed recall (number correct: 0–15)∗ 11.3 (2.8) 4.0% 6.3 (2.8) 56.7%
GIT-II animal naming (number of animal names)‡ 25.5 (5.1) 0.0% 19.2 (5.6) 30.0%
LDST 60 s written (number correct: 0–125)∗§ 33.8 (6.1) 0.0% 23.4 (6.1) 50.0%
CST-C (time in seconds)† 32.1 (11.0) 4.0% 50.1 (18.0) 36.7%
SCWT card III (time in seconds)† 46.7 (43.4) 16.0% 63.3 (21.9) 80.0%
Abbreviations: CST, Concept Shifting Test; GIT, Groningen Intelligence Test; LDST, Letter Digit Substitution Test; SD, standard deviation; SCWT, Stroop Colour-Word Test;
VVLT, Visual Verbal Learning Test; Z ≤ −1, percentage of patients with a Z score of −1 or lower. ∗Higher scores indicate better performance; ‡ Indicates score has no
upper limit; §At least one of out the two LDST 60 subtests had to be scored with a score less than 1.0 SD below the age-, gender- and education-specific mean of the
MAAS study population to have an impaired score on the LDST subtest; †Higher scores indicate worse performance.
FIGURE 1 | (A) Fluid-attenuated inversion recovery (FLAIR) brain magnetic resonance imaging (MRI) scan showing periventricular WMHs and deep WMHs (DWMHs)
in both hemispheres. WMH, white matter hyperintensities; R, right. (B) T2∗-weighted brain MRI scan showing a microbleed located within the right white matter.
R, right. (C) FLAIR brain MRI scan showing a lacune located in the deep gray matter. R, right.
white matter changes (ARWMC) scale was applied to rate
WMHs more specifically per brain region (Wahlund et al.,
2001). PVS (Figure 2) were defined as small, linear or pointy
structures of cerebrospinal fluid intensity measuring <3 mm
in size and following the course of the vessels, at the
level of the basal ganglia and in the centrum semiovale.
T2-weighted images were used in order to rate PVS on a
qualitative scale (Potter et al., 2015). Microbleeds (Figure 1B)
and lacunes (Figure 1C) were rated using T2∗, T2 and
FLAIR images. Microbleeds were defined as small (<5 mm),
homogeneous, round foci of low signal intensity on T2∗ in
the cerebellum, brainstem, basal ganglia, white matter, or
cortico-subcortical junction, differentiated from vessel flow
voids and mineral depositions in the globi pallidi (Wardlaw
et al., 2013a). Lacunes were defined as rounded or ovoid
lesions with diameters from 3 mm to 20 mm located in
the basal ganglia, internal capsule, centrum semiovale, or
brainstem and carefully distinguished from WMH and PVS
(Wardlaw et al., 2013b). An SVD compound score, expressing
the level of cerebral SVD load, was calculated according to
the method of Staals et al. (2014) WMHs and PVS were rated
by two trained raters. In a random sample of one third of
the brain scans, the agreement between raters was high with
intraclass correlation coefficient (ICC) greater than 0.80 for
the Fazekas scale (both PVWMH and DWMH); ICC greater
than 0.75 for the ARWMC except for the basal ganglia
and the infratentorial area; ICC greater than 0.80 regarding
PVS in the basal ganglia and greater than 0.65 in the
centrum semiovale. Microbleeds and lacunes, were rated by
an experienced neurologist (JS). Since one single MRI scanner
performed all measurements no intervariability study was
performed. HCV was measured on T1-weighted images using
the Learning Embeddings Atlas Propagation (LEAP) method
(Wolz et al., 2010a). HCV was normalized by multiplying the
native space volume with the affine scaling factor (ASF), also
derived with LEAP. An ASF value of >1 indicated expansion
and a value <1 contraction required to register each individual’s
brain to the atlas template (Buckner et al., 2004). LEAP data
were provided by Wolz (Ixico Ltd. and Imperial College,
London).
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FIGURE 2 | T2-weighted brain MRI scans showing symmetric
extensive PVS at the level of the basal ganglia (A) and in the centrum
semiovale (B). PVS, perivascular spaces; R, right.
Other Measures
Age, gender, educational level (according to The Dutch Standard
Classification of Education (C.B.S., 2001)), marital status,
visual and hearing impairment, handedness, smoking behavior
and self-reported hypertension and comorbidities (Charlson
Comorbidity Index (Charlson et al., 1987)) were recorded.
Moreover, data on body mass index (BMI), long-term oxygen
therapy, modified Medical Research Council (mMRC) dyspnea
scale (American Thoracic Society, 1982), post-bronchodilator
spirometry (forced vital capacity (FVC), FVC% predicted, forced
expiratory volume in the first second (FEV1), FEV1% predicted
and FEV1/FVC), resting arterial blood gases (arterial oxygen
partial pressure [PaO2], arterial partial pressure of carbon
dioxide [PaCO2] and oxygen saturation [SaO2]), and single
breath carbon monoxide diffusing capacity (DLCO% predicted)
were collected.
Statistical Analyses
All statistical analyses were done using SPSS 21.0 (SPSS Inc.
Chicago, IL, USA). A p-value < 0.05 was considered as
statistically significant. Categorical variables are described as
frequencies, while continuous variables were tested for normality
and are presented as mean and standard deviation (SD) or
median and interquartile range (IQR).
Raw test scores on the neuropsychological test battery were
transformed into age, gender and education corrected Z-scores
based on normative data from the Maastricht Aging Study
(MAAS). Cognitively low-performing individuals had a score less
than 1.0 SD below the age-, gender- and education-specific mean
of the MAAS study population for at least two core tests and
high-performing individuals had a score more than 1.0 SD above
the age-, gender- and education-specific mean of the MAAS
study population for at least two core tests (Table 1; Singh et al.,
2013).
Patient characteristics were compared between the groups
using Chi-square tests for categorical variables and independent
samples t-test or Mann-Whitney U test, as appropriate for
continuous variables. Mann Whitney U tests were performed in
order to compare high and low-performing individuals based
on features of SVD. HCV were compared using independent
samples t-tests. The p-values were adjusted using the Benjamini-
Hochberg correction (Benjamini and Hochberg, 1995) for
multiple tests, with a false discovery rate of 5%.
RESULTS
Patient Characteristics
Cognitively low-performing patients had significantly worse
mean scores on all core tests of the COgnitive-PD test battery
compared to high-performing patients (Table 1). Demographic
and clinical characteristics, including smoking behavior, FEV1,
arterial blood gases and diffusion capacity were comparable
between cognitively high and low-performing patients. The
groups did not differ on reported comorbidities (Table 2).
Structural Brain Abnormalities in High and
Low-Performing Patients with COPD
No differences were seen on the DWMH and PVWMH Fazekas
subscales (Table 3). WMHs mapped specifically per brain region
did not differ between low and high-performing patients. PVS
in basal ganglia or centrum semiovale did not differ between
the groups. There was no difference in presence of lacunes or
microbleeds. The level of cereberal SVD load was comparable
between the two groups. No significant difference was found
between low and high-performing individuals regarding the left
and right HCV (Table 3).
DISCUSSION
Key Findings
The goal of the current brain MRI study was to assess whether
differences in SVD features and/or HCV are related to the level
of cognitive functioning in patients with COPD. In contrast
to our hypothesis that COPD patients with low cognitive
performances are characterized by a higher SVD load, and
smaller HCV compared to COPD patients with high cognitive
performances, we found that structural brain changes were
comparable between COPD patients with low or high cognitively
performance.
We did not find a difference in the compound score
of SVD between high and low-performing COPD patients.
Indeed, SVD may also be found in individuals with normal
cognitive performance (Duning et al., 2005) and the exact
pathophysiological link between SVD features and cognitive
impairment remains not completely understood. It is suggested
that individuals with normal cognitive performance have a
greater cognitive reserve by which they are able to compensate
certain brain pathologies better than others (Stern et al., 2005).
However, the low and high-performing groups in our study were
comparable for educational level, which is considered to be one
on of the best indicators for cognitive reserve. Although not
significant, we observed a trend towards more hypertension, one
of the main risk factors for SVD (Pantoni and Garcia, 1997), in
cognitively low-performing patients. 34.5% of patients without
physician-diagnosed hypertension had an elevated systolic blood
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TABLE 2 | Characteristics of the study population.
Characteristic High-performing COPD
patients (n = 25)
Low-performing COPD
patients (n = 30)
Benjamini-Hochberg
P-value
Demographics
Age, years 60.3 (9.7) 60.6 (6.8) 0.941
Male, n (%) 10 (40.0) 16 (53.3) 0.497
Lower education, n (%) 8 (32.0) 7 (23.3) 0.476
Exacerbation history in the previous 12 months
0–1 exacerbations, n (%) 10 (40.0) 10 (33.3) 0.408
2 ≥ exacerbations, n (%) 15 (60.0) 20 (66.7)
Health condition
Visual impairment, n (%) 4 (16.0) 7 (23.3) 0.524
Hearing impairment, n (%) 6 (24.0) 6 (20.0) 0.612
BMI (kg/m2), mean, (SD) 25.1 (5.2) 27.5 (7.7) 0.458
Oxygen therapy, n (%) 6 (24.0) 3 (10.0) 0.458
mMRC (grade), mean (SD) 2.1 (2.0) 2.6 (2.0) 0.458
Smoking behavior
Current smoker, n (%) 3 (12.0) 7 (23.3) 0.458
Former smoker, n (%) 20 (80.0) 23 (76.7)
Never smoker, n (%) 2 (8.0) 0 (0.0)
Spirometry and arterial blood gases
FEV1/FVC, mean (SD) 37.7 (13.5) 47.0 (14.6) 0.272
FEV1 (% predicted), mean (SD) 50.1 (20.1) 55.6 (20.0) 0.497
SaO2 (%), mean (SD) 93.7 (2.7)∗ 94.0 (2.6) 0.844
SaO2 before 6MWT (%), mean (SD) 94.5 (2.5) 94.3 (2.1) 0.771
88.3 (6.5)
SaO2 after 6MWT (%), mean (SD) 87.8 (7.1) 9.6 (1.5) 0.770
9.3 (1.4)∗
PaO2 (kPa), mean (SD) 9.3 (1.1)‡ 9.7 (1.6)§ 0.458
0.361
PaO2 off-oxygen (kPa), mean (SD) 5.8 (1.8)∗ 6.4 (2.2)
PaCO2 (kPa), mean (SD) 5.8 (2.0)‡ 6.2 (2.1)§ 0.497
49.6 (17.4) 0.534
PaCO2 off-oxygen (kPa), mean (SD) 49.7 (18.6)∗
DLCO (% predicted), mean (SD) 0.988
Comorbidities
Charlson comorbidity index score, mean, (SD) 2.6 (1.6) 3.5 (2.0) 0.425
Myocardial infarction, n (%) 2 (8.0) 10 (33.3) 0.272
Congestive heart failure, n (%) 2 (8.0) 5 (16.7) 0.497
Peripheral vascular disease, n (%) 4 (16.0) 9 (30.0) 0.458
Cerebrovascular disease, n (%) 3 (12.0) 6 (20.0) 0.497
Connective tissue disease, n (%) 6 (24.0) 8 (26.7) 0.631
Peptic ulcer disease, n (%) 4 (16.0) 4 (13.3) 0.631
Mild, moderate or severe liver disease, n (%) 2 (8.0) 0 (0.0) 0.458
Diabetes mellitus, n (%) 3 (12.0) 8 (26.7) 0.458
Hemiplegia, n (%) 2 (8.0) 2 (6.7) 0.705
Moderate to severe chronic kidney disease, n (%) 1 (4.0) 1 (3.3) 0.775
Solid or malignant tumors, n (%) 3 (12.0) 6 (20.0) 0.497
Obstructive sleep apnea, n (%) 3 (12.0) 7 (23.3) 0.476
Hypertension, n (%) 2 (8.0) 11 (36.7) 0.272
HADS anxiety score 6.9 (4.7) 9.1 (4.2) 0.425
HADS anxiety >10 points, n (%) 5 (20.0) 11 (36.7) 0.458
HADS depression score (points) 7.0 (4.6) 7.9 (3.5) 0.553
HADS depression >10 points, n (%) 5 (20.0) 8 (26.7) 0.523
Abbreviations: 6MWT, six-minute walking test; BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in first second;
FVC, forced vital capacity; FEV1/FVC, Tiffeneau index; HADS, Hospital Anxiety Depression Scale; IQR, interquartile range; PaCO2, arterial partial pressure of carbon
dioxide; PaO2, arterial oxygen partial pressure; SaO2, oxygen saturation; SD, standard deviation. ∗n = 24; ‡n = 18; §n = 27.
pressure (≥140) or elevated diastolic blood pressure of ≥90. Yet,
the percentage of patients with elevated systolic or diastolic blood
pressure did not differ between the low and high-performing
group.
When we mapped WMHs specifically per brain region, these
structural brain abnormalities were not able to differentiate
both groups. A population-based study reported that COPD
patients had more severe PVWMHs than persons without
COPD (van Dijk et al., 2004). Characteristics of the control
group were not reported. Our results show no difference
in DWMHs between low and high-performing patients.
Contradictory findings on the differential impact of PVWMHs
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TABLE 3 | SVD and (normalized) hippocampal volume.
High-performing COPD
patients (n = 25)
Low-performing COPD
patients (n = 30)
Benjamini-Hochberg
P-value
SVD
WMH Fazekas scale
PVH, median (IQR) 1.0 (0.0–1.5) 1.0 (0.0–2.0) 0.509
DWMH, median (IQR) 1.0 (1.0–1.0) 1.0 (1.0–2.0) 0.329
WMH ARWMC total, median (IQR) 4.0 (4.0–6.0) 6.0 (3.8–10.0) 0.329
Frontal, median (IQR) Left 1.0 (0.5–1.0) 1.0 (1.0–1.0) 0.329
Right 1.0 (1.0–1.0) 1.0 (1.0–1.0) 0.702
Parietal occipital, median (IQR) Left 1.0 (0.5–1.0) 1.0 (1.0–2.0) 0.329
Right 1.0 (1.0–1.0) 1.0 (1.0–2.0) 0.386
Temporal, median (IQR) Left 0.0 (0.0–0.5) 0.0 (0.0–1.0) 0.329
Right 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.509
Basal ganglia, median (IQR) Left 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.643
Right 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.509
Infratentorial, median (IQR) Left 0.0 (0.0–0.0) 0.0 (0.0–1.0) 0.329
Right 0.0 (0.0–0.0) 0.0 (0.0–1.0) 0.329
PVS
Basal ganglia, median (IQR) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.985
Centrum semiovale, median (IQR) 1.0 (0.0–1.0) 1.0 (0.0–2.0) 0.329
Lacunes, n (%) 5 (20.0) 5 (17.0) 0.792
Microbleeds, n (%) 2 (8.0) 1 (3.3) 0.603
Total SVD score, median (IQR) 1.0 (0.0–2.0) 0.0 (0.0–2.0) 0.761
Hippocampal volume
Left HCV (mm3), mean (SD) 2813.7 (328.1) 2648.8 (328.2) 0.329
Right HCV (mm3), mean (SD) 2834.3 (264.6) 2751.2 (243.0) 0.418
Abbreviations: ARWMC, the age-related white matter changes scale; COPD, chronic obstructive pulmonary disease; DWMH, deep white matter hyperintensity;
HCV, hippocampal volume; PVS, enlarged perivascular spaces; IQR, interquartile range; PVH, periventricular hyperintensity; SD, standard deviation; SVD, small vessel disease.
and DWMHs on cognition exist, probably due to varying
terminology and definitions for PVWMHs and DWMHs
(Kim et al., 2008). Soriano-Raya et al. (2012) suggested
that only DWMHs, not PVWMHs, are related to cognitive
impairments in middle-aged individuals. De Groot et al.
(2000) showed that PVWMHs are associated with cognition
and DWMHs with depression. High and low cognitively
performing COPD patients did not differ on symptoms of
depression.
Van Dijk et al. (2004) did not find an association between
COPD and lacunes. In addition, our study showed no difference
in the incidence of lacunes between high and low-performing
COPD patients. In a large population-based study, a higher
prevalence of cerebral microbleeds was associated with COPD
(Lahousse et al., 2013). Our study did not find differences in
the presence of microbleeds between high and low-performing
COPD patients. It might be that patients with COPD are at risk
for microbleeds due to comorbid processes, such as systemic
inflammation (Maclay and MacNee, 2013) without specific
cognitive consequences.
Finally, no differences in the extent of PVS were found
between high and low-performing patients. The exact causes of
PVS are uncertain but abnormalities at the blood brain interface
and inflammation have been associated with PVS (Wuerfel
et al., 2008; Wardlaw et al., 2009). Studies suggest that smoking
and reduced lung function cause inflammation and that both
variables might act in an additive manner (Gan et al., 2005;
Pelegrino et al., 2013). Our groups were comparable for lung
function and smoking status which might explain the absence of
differences in the extent of PVS.
MRI markers of SVD including WMHs, lacunes and
microbleeds have been related to cognitive performance in
population-based (Prins et al., 2005) and stroke cohorts
(Gregoire et al., 2011; Patel et al., 2013). Yet, effect sizes have
been small across studies (van der Vlies et al., 2012; Kloppenborg
et al., 2014). The relatively weak or inconsistent correlations
may be explained by the fact that it is not the individual lesions
that determine the impact on cognitive performance, but the
cumulative effect of these small, spatially distributed lesions.
This is in line with findings of Schneider et al. (2007) who
demonstrated multiple brain pathologies in cases with dementia
using autopsy.
Rates of hippocampal atrophy are sensitive features of
neurodegeneration. In normal aging (Ystad et al., 2009)
and in several neurological disorders, including AD (Laakso
et al., 1995), temporal lobe epilepsy (Kilpatrick et al., 1997),
and depressed elderly (Steffens et al., 2011), measurements
of volumes of the hippocampus already have been shown
to be positively correlated with impaired performances on
neuropsychological tests, especially in the memory domain.
Also in COPD, HCV may be a proximity marker for cognitive
(memory) impairment. Yet, no differences were observed in left
and right HCV between cognitively low and high-performing
COPD patients. Indeed, compared to cross-sectional studies,
effect sizes are stronger across longitudinal studies (Raz et al.,
2007).
Alternate mechanisms than structural brain abnormalities
may explain cognitive performances are probably multifactorial.
First, worse cognitive performance in the low-performing COPD
group might be explained by damage caused by oxidative stress,
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like oxidized proteins, glycated products and lipid peroxidation
which lead to degeneration of neurons and impairments in
cognitive functioning (Popa-Wagner et al., 2013). Second,
although not significant, the high-performing group more often
received supplemental oxygen. Regular use of supplemental
oxygen therapy has been shown to decrease the risk for cognitive
impairment in patients with COPD (Thakur et al., 2010).
Third, it is possible that the low-performing group had more
comorbidities associated with cognition, other than mentioned
in the Charlson comorbidity index (e.g., osteoporosis and Major
Depressive Disorder) compared to the high-performing group.
Fourth, mitochondrial dysfunction in COPD affects tissues with
high energetic demands such as skeletal muscle, cardiac muscle
and the central nervous system accompanied by cognitive deficits
(Mancuso et al., 2009).
Limitations
Although we used a 3-T MRI scanner, the prevalence of detected
SVD features was rather low. Furthermore, the number of
patients investigated in this study was small and therefore
we might have a low power to detect group differences in
the outcome of interest. However, the group was relatively
homogeneous with regard to demographical and clinical
characteristics. Nevertheless, selection bias cannot be excluded,
because, for instance, patients with personal interest are more
willing to participate. We used visual rating scales, and although
validated, these have some limitations, such as non-linearity
of data, lack of sensitivity to small changes, and subjective
assessment. By using non-parametric tests and calculating an
ICC, we tried to compensate for these limitations. Moreover,
Z scores below −1.0 SD and above +1 SD were considered as
low and high cognitive performance, respectively. These score
cutoff scores may not have been able to differentiate both groups
sufficiently. Yet, Singh et al. (2013) considered a Z scores below
−1.0 SD as being impaired in a COPD population. Though
not the goal of this study, future inclusion of a control group
could provide more insight into COPD specifica brain-cognition
correlations. Additionally, this cross-sectional study can only
determine associations, no causal relationships nor the sequence
of the development of cognitive impairment. Therefore, future
studies should assess cognitive impairment at various stages of
the disease, taking into account varying degrees of hypoxemia.
Conclusions
Using macrostructural MRI features of SVD and HCV, we found
no differences between cognitively low and high-performing
patients with COPD. This suggests that SVD and HCV are
not related to cognitive performance in patients with COPD.
Additional studies will be needed to get a better understanding
of the mechanisms leading to cognitive impairment in COPD
patients, including inflammatory factors, hormonal responses,
metabolic disturbances, (epi)genetic or lifestyle factors, or
microstructural brain changes using Diffusion Tensor Imaging.
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